» Articles » PMID: 34386532

The Immune and Inflammatory Basis of Acquired Pediatric Cardiac Disease

Overview
Date 2021 Aug 13
PMID 34386532
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Children with acquired heart disease face significant health challenges, including a lifetime of strict medical management, multiple cardiac surgeries, and a high mortality risk. Though the presentation of these conditions is diverse, a unifying factor is the role of immune and inflammatory responses in their development and/or progression. For example, infectious agents have been linked to pediatric cardiovascular disease, leading to a large health burden that disproportionately affects low-income areas. Other implicated mechanisms include antibody targeting of cardiac proteins, infection of cardiac cells, and inflammation-mediated damage to cardiac structures. These changes can alter blood flow patterns, change extracellular matrix composition, and induce cardiac remodeling. Therefore, understanding the relationship between the immune system and cardiovascular disease can inform targeted diagnostic and treatment approaches. In this review, we discuss the current understanding of pediatric immune-associated cardiac diseases, challenges in the field, and areas of research with potential for clinical benefit.

Citing Articles

Shear Stress Induces a Time-Dependent Inflammatory Response in Human Monocyte-Derived Macrophages.

Jui E, Kingsley G, Phan H, Singampalli K, Birla R, Connell J Ann Biomed Eng. 2024; 52(11):2932-2947.

PMID: 39289258 DOI: 10.1007/s10439-024-03546-5.


How Do Minerals, Vitamins, and Intestinal Microbiota Affect the Development and Progression of Heart Disease in Adult and Pediatric Patients?.

Brecht P, Dring J, Yanez F, Styczen A, Mertowska P, Mertowski S Nutrients. 2023; 15(14).

PMID: 37513682 PMC: 10384570. DOI: 10.3390/nu15143264.


Cellular mechanisms and molecular pathways linking bitter taste receptor signalling to cardiac inflammation, oxidative stress, arrhythmia and contractile dysfunction in heart diseases.

Welcome M, Dogo D, Nikos E Mastorakis Inflammopharmacology. 2022; 31(1):89-117.

PMID: 36471190 PMC: 9734786. DOI: 10.1007/s10787-022-01086-9.

References
1.
Lipshultz S, Cochran T, Briston D, Brown S, Sambatakos P, Miller T . Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiol. 2013; 9(6):817-48. PMC: 3903430. DOI: 10.2217/fca.13.66. View

2.
Schultheiss H, Fairweather D, Caforio A, Escher F, Hershberger R, Lipshultz S . Dilated cardiomyopathy. Nat Rev Dis Primers. 2019; 5(1):32. PMC: 7096917. DOI: 10.1038/s41572-019-0084-1. View

3.
Kuusisto J, Karja V, Sipola P, Kholova I, Peuhkurinen K, Jaaskelainen P . Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 2012; 98(13):1007-13. PMC: 3368494. DOI: 10.1136/heartjnl-2011-300960. View

4.
Lai S, Marin-Juez R, Stainier D . Immune responses in cardiac repair and regeneration: a comparative point of view. Cell Mol Life Sci. 2018; 76(7):1365-1380. PMC: 6420886. DOI: 10.1007/s00018-018-2995-5. View

5.
Rastogi M, Sarkar S, Makol A, Singh R, Nahar Saikia U, Banerjee D . Anti-endothelial cell antibody rich sera from rheumatic heart disease patients induces proinflammatory phenotype and methylation alteration in endothelial cells. Genes Dis. 2018; 5(3):275-289. PMC: 6176156. DOI: 10.1016/j.gendis.2018.02.002. View